Oncology – Skin
Phase 2 RCT | Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.
19 Sep, 2022 | 12:32h | UTCCombined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial – The Lancet (free registration required for full-text)
Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.
14 Sep, 2022 | 13:01h | UTCSequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Data from the phase II SECOMBIT trial of treatment sequencing for BRAF-mutant metastatic melanoma suggests that nivo+ipi followed by encorafenib + binimetinib results in better OS than the reverse sequence, although with a greater risk of grade 3-4 AEs: https://t.co/9jC2oMI4Az
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.
13 Sep, 2022 | 13:11h | UTCNeoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network
Commentary on Twitter
A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma. #ESMO22 https://t.co/NbICkb5kLM pic.twitter.com/a67fgxKBLy
— NEJM (@NEJM) September 12, 2022
RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.
13 Sep, 2022 | 13:03h | UTCFive-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence
Phase 2 RCT | Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease.
11 Sep, 2022 | 22:25h | UTC
3-year outcomes of a RCT | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma.
2 Sep, 2022 | 13:04h | UTCOriginal Study: Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management.
2 Sep, 2022 | 13:02h | UTC
RCT | Optical coherence tomography vs. punch biopsy for diagnosis of basal cell carcinoma.
31 Aug, 2022 | 11:31h | UTCOptical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma.
26 Aug, 2022 | 13:09h | UTC
RCT | Therapeutic value of sentinel lymph node biopsy in patients with melanoma.
4 Aug, 2022 | 14:05h | UTCTherapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Invited Commentary: Prognostic or Therapeutic—The Role of Sentinel Lymph Node Biopsy in Contemporary Practice – JAMA Surgery (free for a limited period)
Cohort Study | Clinical outcomes and risk stratification of early-stage melanoma micrometastases.
1 Aug, 2022 | 12:04h | UTCClinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
‼️ Patients with low-risk (pT1b-pT2a) #melanoma may still develop high-risk sentinel node metastases ➡️ https://t.co/cBVdpR6xrG #JCO #melsm @marc_moncrieff pic.twitter.com/TW0WHp5brA
— Journal of Clinical Oncology (@JCO_ASCO) July 27, 2022
Cohort Study | Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.
1 Aug, 2022 | 12:03h | UTCCommentary: Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ – AJMC
Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.
1 Aug, 2022 | 11:48h | UTCPhase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)
NICE Guideline Update | Melanoma: assessment and management.
28 Jul, 2022 | 13:21h | UTCMelanoma: assessment and management – National Institute for Health and Care Excellence
RCT | Efficacy and safety of topical hypericin photodynamic therapy for early-stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).
28 Jul, 2022 | 13:09h | UTCEfficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
The findings of this randomized clinical trial indicate that synthetic hypericin photodynamic therapy is effective in early-stage patch and plaque mycosis fungoides−cutaneous T-cell lymphoma and has a favorable safety profile. https://t.co/hHfDESptQF
— JAMA Dermatology (@JAMADerm) July 21, 2022
RCT | Follow-up schedule for patients with sentinel node negative cutaneous melanoma.
25 Jul, 2022 | 12:43h | UTCFollow-up Schedule for Patients with Sentinel Node Negative Cutaneous Melanoma: an International Phase III Randomised Clinical Trial – Annals of Surgery (link to abstract – $ for full-text)
5-year outcomes of a RCT | Encorafenib plus Binimetinib vs. Vemurafenib or Encorafenib in patients with BRAF V600–mutant melanoma.
25 Jul, 2022 | 12:41h | UTC
M-A | Does it really pay-off? Comparison of lymphadenectomy versus observational approach in skin melanoma with positive sentinel node biopsy.
12 Jul, 2022 | 12:37h | UTC
M-A | Associations of thiazide use with skin cancers.
8 Jul, 2022 | 11:55h | UTCAssociations of thiazide use with skin cancers: a systematic review and meta-analysis – BMC Medicine
Related:
Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma – JAMA Internal Medicine
M-A | Adjuvant treatments of adult melanoma.
7 Jul, 2022 | 12:12h | UTC
Consensus Guideline: Diagnosis and treatment of Merkel cell carcinoma.
28 Jun, 2022 | 11:07h | UTC
Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.
23 Jun, 2022 | 09:57h | UTC
ASCO Guideline Update: Systemic therapy for melanoma.
14 Jun, 2022 | 11:00h | UTC
Systematic Review: Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings.
10 Jun, 2022 | 10:28h | UTC
Commentary on Twitter
NEW Review: '#ArtificialIntelligence and #MachineLearning algorithms for early detection of #skincancer in community and primary care settings: a systematic review'. @Cambridge_Uni @OUHospitals @UniMelb @UniofNottingham @QMUL_WIPH https://t.co/LQuzNbrKpn pic.twitter.com/v83GDEg2G4
— The Lancet Digital Health (@LancetDigitalH) May 26, 2022
RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.
2 Jun, 2022 | 10:41h | UTC
Commentary on Twitter
In this RCT, adjunctive use of reflectance confocal microscopy for suspicious lesions is proven to reduce unnecessary excisions and removes all aggressive melanomas at baseline in a real-life, prospective clinical decision making setting. https://t.co/cWJu9TlaEH
— JAMA Dermatology (@JAMADerm) June 1, 2022